1st Department of Medicine, Division of Hematology, Faculty Hospital of Charles University. Plzeň, ČSFR. Blood Bank, Faculty Hospital of Charles University, Plzeň, ČSFR
22 patients with acute myelogenous leukemia were treated with one induction course of the 7 + 3 regimen and two postremission courses of intermediate dose ara-c and mitoxantrone. The ccnsumpticn of red cell transfusions, the risk of alloimunizaticn and the benifit of HLA matching and platelet, crossmatching was observed. 584 red blood cell transfusions and 418 single platelet transfusions were applied. In 8 patients (36 %) lymphocytotoxic antibodies were established. 36 crossmatch — compatible platelet transfusions were applied in these cases. The probability to find a crossmatch — compatible donor in a group of random donors was 50 % on average. Sufficient corrected count increament (CCI) was established after 26 of these 36 transfusions. From 10 transfusions with insufficient CCI 7 were applied in febrile patients. In our register of 1000 HLA typed donors only 2 HLA-A and HLA-B matched donors were found.
The risk of alloimmunization during the intensive postremission therapy of acute leukemias
